Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia | Zendy

Iain J. Abbott | Zendy; Adam Jenney | Zendy; Cameron J. Jeremiah | Zendy; Mirjana Mirčeta | Zendy; J. Kandiah | Zendy; Deborah C. Holt | Zendy; Steven Y. C. Tong | Zendy; Denis W. Spelman | Zendy

Open Access

Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia

Author(s) -

Iain J. Abbott,

Adam Jenney,

Cameron J. Jeremiah,

Mirjana Mirčeta,

J. Kandiah,

Deborah C. Holt,

Steven Y. C. Tong,

Denis W. Spelman

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02015-15

Subject(s) - etest , microbiology and biotechnology , staphylococcus aureus , methicillin resistant staphylococcus aureus , multiple drug resistance , antibiotics , biology , bacteria , genetics

A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, >1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P < 0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research